- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01404988
Veterans Intensive Personalized Treatment in Heart Failure (VIP)
VIP (Veterans Intensive Personalized) Treatment in Heart Failure
Přehled studie
Postavení
Podmínky
Detailní popis
OBJECTIVES: In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life (QOL) in veterans with heart failure (HF). This theory-based pilot 3-arm randomized controlled trial (RCT) will base one active arm on the Transtheoretical Model (TTM), while the other active arm will add environmental (built and human) tailoring to TTM. The overarching hypothesis driving this proposal is that a behavioral intervention (BI), which uses the TTM, or a behavioral and environment-tailored intervention (BEI) will lower HF recurrence and improve QOL by better medication and diet adherence compared to attention control.
RESEARCH DESIGN: This is a practice-based RCT to test the effect of BI and BEI on medication and diet adherence. The study is embedded in typical VA healthcare with all 3 arms incorporating the enhancements in HF care that have been implemented including the Patient Aligned Care Teams (PACT), system redesign methods to improve HF care, ongoing HF quality improvement and Telehealth. We will randomize 99 participants equally to BI, BEI and AP. All analyses will be intent to treat.
METHODOLOGY: The study sites will be the VAMC's at Manhattan and Brooklyn. Participants will be veterans with classes I-III HF with prescribed HF medication for 6 months. Men and women ( 21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III are eligible. They must have an available phone and 2 clinic visits in the previous 1.5 years. Patients with poor short-term survival (< 1 year), recent major surgery (< 3 months), temporarily in the area, or those unable to provide consent will be excluded. After being screened for eligibility, participants will come in for 2 study visits over the course of 6 months which will last about 1.5-2 hours. At each visit, a research assistant (RA) will administer a questionnaire assessing health behaviors including diet, exercise and medication and quality of life. The RAs will also measure height, weight, take 6 BP readings, and send patients to the lab for blood and urine samples. After the first clinic visit, participants will be randomized to one of three telephone groups. All participants will receive 1 phone call per month for 6 months which will last approximately 30-40 minutes. 1) The BI group will receive TTM stage-matched counseling. The interventionist will assess how ready patients are for change in terms of diet, medication, and exercise adherence and deliver a tailored intervention discussing adherence barriers. 2) In the BEI, in addition to using the TTM, the intervention will tailor environmental factors, such as availability of healthy food stores, recreational facilities, and support from caregivers in helping participants follow treatment recommendations. We will speak with participant's caregivers to educate them on heart failure as well. The caregivers will receive a call every 2 months (3 in total) lasting approximately 20-30 minutes. 3) The control group will receive monthly telephone calls during which they will receive general health education. Our primary analytic goal is to estimate the medication adherence rate and QOL to power a larger study. We will also perform 1-sample Exact Binomial Tests comparing the active arms to the expected inactive control rate of 47%. Since this is a pilot study, we will use a 5% type 1 error rate (2-sided) for each test. All analyses will be intent to treat.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
New York
-
New York, New York, Spojené státy, 10010
- VA New York Harbor Health Care System
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Men and women (21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III.
- They must have an available phone and 2 clinic visits in the previous 1.5 years.
Exclusion Criteria:
- Patients with poor short-term survival (< 1 year)
- recent major surgery (< 3 months)
- temporarily in the area
- or those unable to provide consent will be excluded.
- Patients excluded and reason for exclusion will be recorded.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Telephone-Delivered BI
Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
|
Behavioral Intervention will be delivered over the phone.
|
|
Experimentální: Telephone-Delivered BEI
Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring.
Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities.
Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support.
Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
|
Behavioral and Environmental Intervention will be delivered over the phone
|
|
Komparátor placeba: Telephone-Delivered API
Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
|
Attention Placebo Intervention will be delivered over the phone
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Medication Adherence (Refill Compliance for All HF Medications)
Časové okno: 6 months from baseline visit
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months from baseline visit
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Adherence to ACE Inhibitors and ARB
Časové okno: 6 months after baseline
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months after baseline
|
|
Adherence to Beta Blockers
Časové okno: 6 months from baseline
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months from baseline
|
|
Self-reported Medication Adherence
Časové okno: 6 months from baseline
|
Assessed using Morisky medication-taking scale.
Higher score corresponds to worse adherence.
|
6 months from baseline
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Sundar Natarajan, MD MSc, VA New York Harbor Health Care System
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- RRP 11-238
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Srdeční selhání
-
Region SkaneZápis na pozvánkuSrdeční selhání New York Heart Association (NYHA) třída II | Srdeční selhání New York Heart Association (NYHA) třída IIIŠvédsko
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... a další spolupracovníciUkončenoSrdeční selhání, systolické | Srdeční Selhání Se Sníženou Ejekční frakcí | Srdeční selhání New York Heart Association Třída IV | Srdeční selhání New York Heart Association Třída IIIPolsko
-
Novartis PharmaceuticalsDokončenoPacienti, kteří úspěšně dokončili 12měsíční léčebné období základní studie (de Novo Heart Recipients), kteří měli zájem o léčbu EC-MPS
-
University of WashingtonAmerican Heart AssociationDokončenoSrdeční selhání, městnavé | Mitochondriální alterace | Srdeční selhání New York Heart Association Třída IVSpojené státy
-
Portuguese Association of Interventional CardiologyMedtronicNáborTěžká symptomatická aortální stenóza (definována jako třída New York Heart Association (NYHA) ≥ II)Portugalsko
Klinické studie na Telephone-Delivered BI
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončenoNovotvaryŠpanělsko, Spojené státy, Spojené království
-
Boehringer IngelheimAktivní, ne náborMelanom | Nemalobuněčný karcinom plic (NSCLC) | Karcinom, skvamózní buňky hlavy a krku (HNSCC)Holandsko
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimDokončeno
-
Boehringer IngelheimStaženoSpinocelulární karcinom análního kanáluKorejská republika
-
Boehringer IngelheimDokončeno